Arcadia Investment Management Corp MI Sells 285 Shares of AbbVie Inc. $ABBV

Arcadia Investment Management Corp MI cut its stake in AbbVie Inc. (NYSE:ABBV) by 5.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,020 shares of the company’s stock after selling 285 shares during the quarter. Arcadia Investment Management Corp MI’s holdings in AbbVie were worth $932,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. RAM Investment Partners LLC increased its stake in AbbVie by 7.7% during the 2nd quarter. RAM Investment Partners LLC now owns 6,358 shares of the company’s stock worth $1,180,000 after acquiring an additional 453 shares during the period. Advisors Capital Management LLC lifted its position in shares of AbbVie by 2.0% during the 2nd quarter. Advisors Capital Management LLC now owns 591,096 shares of the company’s stock valued at $109,719,000 after acquiring an additional 11,317 shares during the period. WP Advisors LLC grew its holdings in shares of AbbVie by 1.4% during the 2nd quarter. WP Advisors LLC now owns 34,347 shares of the company’s stock worth $6,376,000 after purchasing an additional 487 shares in the last quarter. Grandfield & Dodd LLC increased its position in shares of AbbVie by 3.2% in the second quarter. Grandfield & Dodd LLC now owns 5,707 shares of the company’s stock worth $1,059,000 after purchasing an additional 175 shares during the period. Finally, Phoenix Wealth Advisors raised its stake in AbbVie by 623.4% in the second quarter. Phoenix Wealth Advisors now owns 14,026 shares of the company’s stock valued at $2,603,000 after purchasing an additional 12,087 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Trading Up 0.1%

NYSE ABBV opened at $232.43 on Friday. The company has a market capitalization of $410.79 billion, a price-to-earnings ratio of 110.68, a PEG ratio of 1.42 and a beta of 0.50. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a twelve month low of $163.81 and a twelve month high of $244.81. The stock’s 50-day simple moving average is $224.89 and its two-hundred day simple moving average is $203.90.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.AbbVie’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s dividend payout ratio is presently 524.24%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ABBV. Scotiabank assumed coverage on shares of AbbVie in a research note on Thursday. They set a “sector outperform” rating and a $280.00 price objective on the stock. Wells Fargo & Company increased their price target on shares of AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a research report on Friday, September 12th. JPMorgan Chase & Co. lifted their price objective on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. BMO Capital Markets upped their target price on AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a research note on Friday, September 12th. Finally, Berenberg Bank raised AbbVie from a “hold” rating to a “buy” rating and raised their target price for the company from $170.00 to $270.00 in a report on Wednesday, September 17th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $240.14.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.